Dr. Mosaad Morsi
Chairman of Pharma-Med
Dr. Mosaad Morsi is an accomplished member of the pharmaceutical industry in the Middle East region, holding several leading positions within the medical and regulatory fields for 23 years at Pfizer-Middle East and Sanofi-Egypt.
He was the medical and regulatory affairs director of Sanofi Egypt for 10 years and also held several positions at Pfizer Middle East, including the medical director and clinical research director positions, for a total of 13 years. Furthermore, he was designated team leader of a novel medicinal product for Pfizer Africa, Middle East, India and Pakistan.
Dr. Mosaad Morsi completed his MB BCh from Cairo University, holds an MSc in Dermatology and Venereology from Al Azhar University, and practiced medicine for several years in Egypt, Saudi Arabia and Kuwait.
After joining the industry, he became actively involved in clinical research as well as medical and regulatory fields, and developed a comprehensive understanding of the standards imposed by both local and international regulatory bodies. He received extensive training on ICH/GCP guidelines and clinical research management, and conducted basic and advanced GCP training programs to hundreds of physicians and investigators in the Middle East. Throughout his career, he has successfully managed numerous clinical studies at different phases of drug development by ensuring full compliance with ethics and quality standards.
Dr. Mosaad Morsi is currently the Chairman and CEO of a number of companies, offering a wide range of support services to the pharmaceutical industry, medical community, and academia. These companies include:
- Pharmamed: Medical Translation Services
- RAY: Clinical Research Services (RAY-CRO) and Patient Support Services (RAY-PSP)
- Dataclin: Contract Research Organization
- Zi-Diligence: Bio-analytical Center
- Clin-m: Clinical Supplies Management
His primary goal is to promptly and continually improve the overall quality of scientific research and healthcare services, ultimately improving patient outcomes. He remains committed to implementing a patient-centered approach through ethics, quality and compliance.